FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
about
Molecularly targeted drugs for metastatic colorectal cancerEndothelial fatty acid transport: role of vascular endothelial growth factor BCompensatory angiogenesis and tumor refractorinessAngiogenesis in metastatic colorectal cancer and the benefits of targeted therapyNewly discovered angiogenesis inhibitors and their mechanisms of actionResistance and escape from antiangiogenesis therapy: clinical implications and future strategiesThe glomerulopathy of sickle cell diseaseEscaping Antiangiogenic Therapy: Strategies Employed by Cancer CellsThe coordinated p53 and estrogen receptor cis-regulation at an FLT1 promoter SNP is specific to genotoxic stress and estrogenic compoundAnti-cancer activity of an osthole derivative, NBM-T-BMX-OS01: targeting vascular endothelial growth factor receptor signaling and angiogenesisPlacental growth factor contributes to micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic retinopathyGenetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study.Molecular mechanisms and clinical applications of angiogenesisAntiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Systems biology of pro-angiogenic therapies targeting the VEGF systemNormalization of the vasculature for treatment of cancer and other diseases.EFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE.Role of placenta growth factor in cancer and inflammation.VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation.From combinatorial peptide selection to drug prototype (I): targeting the vascular endothelial growth factor receptor pathway.Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer.Indolyl-quinuclidinols inhibit ENOX activity and endothelial cell morphogenesis while enhancing radiation-mediated control of tumor vasculature.Network Analysis Reveals A Signaling Regulatory Loop in the PIK3CA-mutated Breast Cancer Predicting Survival Outcome.VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy.Notch regulates the angiogenic response via induction of VEGFR-1.Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.FLT1 genetic variation predisposes to neovascular AMD in ethnically diverse populations and alters systemic FLT1 expression.Vascular endothelial growth factor-B gene transfer exacerbates retinal and choroidal neovascularization and vasopermeability without promoting inflammation.Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement.Heme-bound iron activates placenta growth factor in erythroid cells via erythroid Krüppel-like factorSignificance of immunohistochemistry in breast cancerβ-hairpin peptide that targets vascular endothelial growth factor (VEGF) receptors: design, NMR characterization, and biological activityUrinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fms-like tyrosine kinase-1.Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors.A general approach for receptor and antibody-targeted detection of native proteins utilizing split-luciferase reassembly.Endothelial cell metabolism: parallels and divergences with cancer cell metabolismPlacental growth factor mediates aldosterone-dependent vascular injury in mice.The discovery of placenta growth factor and its biological activity.Nuclear receptor COUP-TFII controls pancreatic islet tumor angiogenesis by regulating vascular endothelial growth factor/vascular endothelial growth factor receptor-2 signaling
P2860
Q26828735-8A22107F-2245-4D4A-AC49-868D370CB7F1Q26829121-7DF75906-9A2D-46CF-B646-5A401382E5D2Q26851916-746B42DB-FA7F-48D1-9B62-01E87582E5D4Q26853604-820F9E0A-6B53-4225-9029-DF26BEB46BF9Q26998498-7CE55B60-663F-4E0C-B9D2-FBB51B2A1A38Q27016629-119FF462-39FF-41D3-897E-4EC42DC4928FQ27023071-C27A48C2-8882-4D94-984A-25E61757251EQ28067753-885CEE46-C6B6-4B62-976C-F5C9AFF9D92CQ28473733-C85764FA-BA5F-4BE5-93E5-C80DAD23D7EAQ28535457-8DF68864-215B-4F0D-9D29-96266C5C3501Q28565180-5083A27A-B8BA-4552-B013-5E3B71972EF7Q29417068-240FA6A4-984A-4635-B96B-400B7E389505Q29547314-0014CE82-F7A2-430B-BBBA-74A55B459170Q30399006-E6CFF429-AD4B-4784-8992-1B83F5856B73Q30430112-9D5F0EFF-2CE5-48A4-A111-5499364E82F4Q30471456-CDC16DDE-2379-4733-9265-B1B209A9EFCAQ30490563-0CF8B0EB-AB3E-4B2E-8D6C-3CF74921FACFQ33352793-541232B1-AB55-4127-A304-4DA81817269BQ33504611-2DE9E038-7924-4EC7-9E70-C5ABE1A14BDAQ33535171-15EF0D3B-4967-49BE-AB11-65544B664AC8Q33539996-1D4AA826-AC51-4031-9746-52C0A37E50F0Q33552232-EBAA7FFA-15A6-435E-8206-CFFE317723E2Q33631628-02EECCD3-F1A2-405E-B1EC-55F7C1D67B18Q33640270-BAE3BDF5-499D-42DF-A5B4-240E67DFE440Q33689928-3D2561ED-4ADD-4B3D-9CFD-4691FE25690BQ33760923-0876ECA1-BD72-46EC-9BA6-3C8C6A3B8B78Q33770680-A7A4BC79-C2A3-47B2-9E85-45A0B3BF3803Q33816926-38431AD6-2369-442D-8E04-95BBBD4055ADQ33834038-0C23EEC4-2907-4028-858C-6E552F5D2DBDQ34000345-B5E528ED-E742-49B2-B993-D20D891B360BQ34019609-6EF0ACE0-FD02-446D-96F7-AC9715938CC2Q34023682-2D2121EF-E98F-4F74-8514-72380659B2F0Q34039282-45640136-AD10-413B-8E03-621787159F65Q34073285-73ADC43C-0DD9-4585-89E0-E13E6187DFBAQ34152009-BD53BE42-5F2D-44B1-A514-278B2B211DD9Q34204188-7A32B359-912D-4296-9F1B-50B670BA4115Q34228247-7AC0F505-47E5-4F5A-8988-B09367EFEEC5Q34245292-DA3BBBF8-2C7E-402C-966B-7347E60C7CDEQ34245619-64807DBA-7F05-48F7-8F49-0EF162051962Q34267968-57CAEF10-8E05-4D63-B0E7-9006A71D2965
P2860
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
@en
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
@nl
type
label
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
@en
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
@nl
prefLabel
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
@en
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
@nl
P2093
P356
P1476
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
@en
P2093
Bart Jonckx
Christian Fischer
Massimiliano Mazzone
P2888
P304
P356
10.1038/NRC2524
P407
P577
2008-12-01T00:00:00Z